Regeneron Pharmaceuticals, Inc.

Jeanette L Fairhurst

Joel H Martin

Nicholas J Papadopoulos

Tammy T Huang

Sean Stevens

Kevin J Pobursky

Margaret Karow

Ashique Rafique

Eric L Smith

Gang Chen

James P Fandl

Joan A Windsor

Warren R Mikulka

Allen Radin

Ergang Shi

Raymond W Leidich

Diana M Ahrens

Marcela Torres

Tammy H Huang

William C Olson

Sokol Haxhinasto

Elena Garnova

George D Yancopoulos

Eric B Smith

Warren R Mikluka

Eric Smith

The present invention provides nucleic acid molecules that encode antibodies or antigen-binding fragments thereof, which specifically bind human interleukin-4 receptor (IL-4R). Also provided are expression vectors comprising nucleic acid molecule that encode anti-IL-4R antibodies, host cells comprising the expression vectors, and methods of producing anti-IL-4R antibodies or antigen-binding fragments thereof comprising growing the host cells under conditions permitting production of the antibody or fragment, and recovering the antibody or fragment so produced.

High affinity human antibodies to human IL-4 receptor

The present invention provides antibodies and antigen-binding fragments (e.g., human antibodies) that bind specifically to human Interleukin-36 receptor (IL36R). Methods for treating or preventing diseases mediated by IL36R (e.g., skin or colon inflammatory conditions such as palmo-plantar pustular psoriasis, palmoplantar pustulosis, generalized pustular psoriasis, ulcerative colitis or IBD) using the antibodies and fragments are also provided along with methods of making the antibodies and fragments.

Anti-IL36R antibodies

A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a Kof about 500 pM or less and blocks IL-6 activity with an ICof 200 pM or less, is provided. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.

High affinity antibodies to human IL-6 receptor

Nucleic acids encoding high affinity antibodies to human IL-6 receptor

The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (NSAID), a glucocorticoid, a disease-modifying anti-rheumatic drug (DMARD), or a TNF-alpha antagonist, T-cell blocker, anti-CD20 antibody, an IL-1, JAK or IL-17 antagonist, or any combination thereof.

Method of treating rheumatoid arthritis with an anti-IL-6R antibody

The present invention provides methods for treating one or more diseases or disorders which are improved, inhibited or ameliorated by reducing interleukin-4 (IL-4) activity. The methods of the invention comprise administering to a patient an antibody, or antigen-binding fragment thereof, which specifically binds to a human IL-4 receptor.

An isolated human antibody or antigen binding fragment thereof which binds to human interleukin-4 receptor alpha (hIL-4R&#x3b1;) with an affinity constant (K) of less than 200 pM, as measured by surface plasmon resonance, is provided.

An isolated antibody or antibody fragment that binds human interleukin-18 receptor alpha (hIL-18R&#x3b1;), comprising a light chain variable region (LCVR) selected from the group consisting of SEQ ID NO: 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 61, 65, 69, 73, 77, and 81 and/or a heavy chain variable region (HCVR) selected from the group consisting of SEQ ID NO: 3, 7, 11, 15, 19, 23, 27, 31, 35, 39, 43, 47, 51, 55, 59, 63, 67, 71, 75, and 79, or a fragment or sequence modified by an amino acid substitution, deletion or addition thereof.

High affinity human antibodies to human IL-18 receptor

Growing community of inventors

White Plains, NY, United States of America

Jeanette L Fairhurst